« Back
Home /
A 83-01

A 83-01

Item no.	HY-10432-5mg
Manufacturer	MedChem Express
CASRN	909910-43-6
Amount	5 mg
Quantity options	100 mg 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.33
Citations	[1]Tojo M, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 2005 Nov;96(11):791-800.\|[2]Yamamura S, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012 Jan 1;130(1):20-8.\|[3]Taniguchi Y, et al. Enhanced antitumor efficacy of folate-linked liposomal Adriamycin with TGF-β type I receptor inhibitor. Cancer Sci. 2010 Oct;101(10):2207-13. Acta Pharm Sin B. 2025 Sep 19. Acta Pharmacol Sin. 2024 Dec;45(12):2611-2624. Acta Pharmacol Sin. 2025 May;46(5):1404-1418. Adv Sci (Weinh). 2022 Sep;9(26):e2202505. Adv Sci (Weinh). 2024 Dec 4:e2408852. Adv Sci (Weinh). 2024 Nov 25:e2401227. Adv Sci (Weinh). 2024 Nov;11(43):e2402299. Adv Sci (Weinh). 2025 Nov 3:e09151. Am J Physiol Cell Physiol. 2023 Jul 1;325(1):C344-C361. Biofabrication. 2025 Aug 12;17(4). Biol Reprod. 2025 May 13:ioaf108. Biomed Pharmacother. 2025 May 1:187:118094. bioRxiv. 2024 August 11. bioRxiv. 2024 Feb 27. bioRxiv. 2024 July 22. bioRxiv. 2024 November 18. bioRxiv. 2025 April 14. bioRxiv. 2025 April 30. bioRxiv. 2025 Aug 30. bioRxiv. 2025 Aug 8:2025.08.08.669417. bioRxiv. 2025 January 28. bioRxiv. 2025 May 12. Br J Cancer. 2025 Aug 26. Br J Cancer. 2025 Jan;132(1):126-136. Cancer Biomark. 2025 Oct;42(10):18758592251390145. Cancer Commun (Lond). 2025 Nov 10. Cancer Res. 2025 May 2;85(9):1628-1643. Cancer Res. 2025 Nov 6. Cancer Res. 2025 Oct 9. Cell Death Dis. 2024 Aug 3;15(8):559. Cell Death Dis. 2025 Aug 30;16(1):660. Cell Prolif. 2023 Jan;56(1):e13320. Cell Prolif. 2024 Jun;57(6):e13599. Cell Rep Med. 2025 Feb 18;6(2):101966. Cell Rep. 2022 Jul 12;40(2):111053. Cell Rep. 2023 May 23;42(6):112546. Cell Stem Cell. 2022 Sep 1;29(9):1346-1365.e10. Cell Stem Cell. 2025 Mar 6;32(3):391-408.e11. Cell Stem Cell. 2025 Mar 6;32(3):409-425.e8. Cell. 2024 Nov 14;187(23):6566-6583.e22. Cells. 2024 Aug 31. Commun Biol. 2025 Jul 4;8(1):995. Engineering. 2025 Aug 27. FASEB J. 2020 Aug;34(8):11185-11199. FASEB J. 2023 Dec;37(12):e23279. FASEB J. 2023 Jul;37(7):e22983. Front Med. 2021 Sep 23;8:746298. Genome Med. 2024 Apr 24;16(1):60 Gynecol Oncol. 2019 Jun;153(3):639-650. Hum Cell. 2024 Nov 4;38(1):13. In Vitro Model. 2025 Mar 5;4(1):31-44. Int J Cancer. 2024 May 15;154(10):1814-1827. Int J Mol Sci. 2023 Dec 29;25(1):477. Int J Mol Sci. 2025 May 31;26(11):5306. Int J Radiat Oncol Biol Phys. 2024 Mar 1;118(3):817-828. iScience. 2025 Apr 3;28(5):112344. iScience. 2025 Jan 17;28(2):111827. iScience. 2025 Oct 17. J Pharm Anal. 2024 Mar;14(3):335-347. J Transl Med. 2021 Dec 7;19(1):497. J Vis Exp. 2025 Jan 31:(215). Methods Mol Biol. 2022:2454:811-827. Methods Mol Biol. 2024:2767:1-18. Methods Mol Biol. 2024:2767:43-52. Methods Mol Biol. 2024:2767:53-62. Methods Mol Biol. 2025 May 17. Methods Mol Biol. 2025 May 22. Mol Cancer. 2024 Jan 10;23(1):12. Mol Oncol. 2024 Mar;18(3):547-561. Nano Res. 03 August 2022. Nat Cell Biol. 2022 Jun;24(6):858-871. Nat Commun. 2022 Sep 6;13(1):5237. Nat Commun. 2025 Aug 26;16(1):7954. Nat Genet. 2024 Feb;56(2):294-305. Nat Methods. 2025 Mar;22(3):510-519. Nat Photonics. 2025 Jul 10. Nat Protoc. 2023 May;18(5):1584-1620. Patent. US20220389379A1. Patent. US20240319170A1 Patent. US20240344020A1 Patent. US20240344020A1. Patent. US20250129329A1. Redox Biol. 2025 Jun:83:103615. Reprod Toxicol. 2024 Jan:123:108522. Res Sq. 2025 Jul 14. Research Square Preprint. 2021 Jan. Sci Adv. 2021 Apr 14;7(16):eabb2213. Sci Adv. 2023 Dec 22;9(51):eadi5683. Sci Adv. 2025 May 9;11(19):eadr3173. Sci Adv. 2025 Sep 5;11(36):eadz0808. Sci Rep. 2025 Mar 12;15(1):8531. SSRN. 2024 May 23. SSRN. 2024 May 30. SSRN. 2025 Jun 3. SSRN. 2025 May 27. Stem Cell Res Ther. 2024 Dec 18;15(1):478. Stem Cell Res Ther. 2025 Mar 11;16(1):132. Stem Cell Res Ther. 2025 Oct 8;16(1):547. Stem Cells Int. 2025 Jul 11:2025:5105796. Theranostics. 2021 Mar 14;11(11):5539-5552. Theranostics. 2024 Jan 1;14(3):1049-1064. University of California. 2025. Cell Signal. 2025 Jun 17:111946. Genes Dis. 2025 May 2. J Biol Chem. 2022 Sep;298(9):102374. Nat Commun. 2025 Jul 17;16(1):6575. Science. 2020 Dec 4;370(6521):eaay2002.
Smiles	S=C(N1N=C(C2=NC(C)=CC=C2)C(C3=CC=NC4=CC=CC=C34)=C1)NC5=CC=CC=C5
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	909910-43-6
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds
Manufacturer - Targets	Organoid; TGF-β Receptor
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	421.52
Product Description	A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Stem Cell/Wnt; TGF-beta/Smad
Clinical information	No Development Reported
Isoform	ALK4; ALK5; ALK7
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.